参考文献
[1]Leise MD,Poterucha JJ,Talwalkar JA.Drug-induced liver injury.Mayo Clin Proc 2014;89:95-106.
[2]肝衰竭诊治指南2012[S].中华临床感染病杂志,2012,5:321-327.
[3]Siddiqui MS,Stravitz RT.Intensive care unit management of patients with liver failure.Clin Liver Dis 2014;18:957-978.
[4]Willars C.Update in intensive care medicine:Acute liver failure.Initial management,supportive treatment and who to transplant.Curr Opin Crit Care 2014;20:202-209.
[5]葛均波,徐永健主编.内科学[M].第八版.北京:人民卫生出版社,2013:419-428.
[6]Liou IW.Management of end-stage liver disease.Med Clin North Am 2014;98:119-152.
[7]Bendtsen F,Gronbaek H,Hansen JB,Aagaard NK,Schmidt L,Moller S.Treatment of ascites and spontaneous bacterial peritonitis-part i.Dan Med J 2012;59:C4371.
[8]Hsu SJ,Huang HC.Management of ascites in patients with liver cirrhosis: Recent evidence and controversies.J Chin Med Assoc 2013;76:123-130.
[9]Runyon BA,Aasld.Introduction to the revised american association for the study of liver diseases practice guideline management of adult patients with ascites due to cirrhosis 2012.Hepatology 2013;57:1651-1653.
[10]Gines P,Quintero E,Arroyo V,et al.Compensated cirrhosis: Natural history and prognostic factors.Hepatology 1987;7:122-128.
[11]Runyon BA.Care of patients with ascites.N Engl J Med 1994;330:337-342.
[12]Runyon BA,Committee APG.Management of adult patients with ascites due to cirrhosis: An update.Hepatology 2009;49:2087-2107.
[13]Gaglio P,Marfo K,Chiodo J,3rd.Hyponatremia in cirrhosis and end-stage liver disease:Treatment with the vasopressin v(2)-receptor antagonist tolvaptan.Dig Dis Sci 2012;57:2774-2785.
[14]蒋朱明主编.临床水与电解质平衡[M].第3 版.北京:人民卫生出版社,2013:261-281.
[15]Angeli P,Wong F,Watson H,Gines P.Hyponatremia in cirrhosis:Results of a patient population survey.Hepatology 2006;44:1535-1542.(https://www.daowen.com)
[16]Cardenas A,Gines P,Marotta P,et al.Tolvaptan,an oral vasopressin antagonist,in the treatment of hyponatremia in cirrhosis.J Hepatol 2012;56:571-578.
[17]Ahya SN,Jose Soler M,Levitsky J,Batlle D.Acid-base and potassium disorders in liver disease.Semin Nephrol 2006;26:466-470.
[18]Funk GC,Doberer D,Kneidinger N,Lindner G,Holzinger U,Schneeweiss B.Acid-base disturbances in critically ill patients with cirrhosis.Liver Int 2007;27:901-909.
[19]Funk GC,Doberer D,Osterreicher C,Peck-Radosavljevic M,Schmid M,Schneeweiss B.Equilibrium of acidifying and alkalinizing metabolic acid-base disorders in cirrhosis.Liver Int 2005;25:505-512.
[20]Sussman AN,Boyer TD.Management of refractory ascites and hepatorenal syndrome.Curr Gastroenterol Rep 2011;13:17-25.
[21]Barbano B,Sardo L,Gigante A,et al.Pathophysiology,diagnosis and clinical management of hepatorenal syndrome:From classic to new drugs.Curr Vasc Pharmacol 2014;12:125-135.
[22]Angeli P,Merkel C.Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis.J Hepatol 2008;48 Suppl 1:S93-103.
[23]Fabrizi F,Aghemo A,Messa P.Hepatorenal syndrome and novel advances in its management.Kidney Blood Press Res 2013;37:588-601.
[24]Arroyo V,Gines P,Gerbes AL,et al.Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis.International ascites club.Hepatology 1996;23:164-176.
[25]Salerno F,Gerbes A,Gines P,Wong F,Arroyo V.Diagnosis,prevention and treatment of hepatorenal syndrome in cirrhosis.Gut 2007;56:1310-1318.
[26]Easl clinical practice guidelines on the management of ascites,spontaneous bacterial peritonitis,and hepatorenal syndrome in cirrhosis.J Hepatol 2010;53:397-417.
[27]Moreau R,Lebrec D.Acute renal failure in patients with cirrhosis:Perspectives in the age of meld.Hepatology 2003;37:233-243.
[28]Gines A,Escorsell A,Gines P,et al.Incidence,predictive factors,and prognosis of the hepatorenal syndrome in cirrhosis with ascites.Gastroenterology 1993;105:229-236.
[29]Nassar Junior AP,Farias AQ,LA DA,Carrilho FJ,Malbouisson LM.Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: A systematic review and meta-analysis.PLoS One 2014;9:e107466.
[30]Angeli P,Volpin R,Gerunda G,et al.Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.Hepatology 1999;29:1690-1697.